Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Keyword(s):
Keyword(s):
Keyword(s):
2007 ◽
Vol 5
(4)
◽
pp. 362
◽
Keyword(s):
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8056-8056
◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8046-8046
◽
Keyword(s):
2019 ◽
Vol 25
(7)
◽
pp. 2088-2095
◽
Keyword(s):
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. LBA7512-LBA7512
◽
Keyword(s):